289 results on '"Myelodysplastic syndromes -- Care and treatment"'
Search Results
2. Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review
3. Study Results from Yale University Update Understanding of Myelodysplastic Syndromes (Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities)
4. University of Texas MD Anderson Cancer Center Researchers Provide New Study Findings on Myelodysplastic Syndromes (Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with ...)
5. Yuncheng Central Hospital Researchers Add New Data to Research in Myelodysplastic Syndromes [Iron overload impact on peripheral blood cells, lymphocytes and karyotypes in newly diagnosed myelodysplastic syndromes (MDS) patients: a single-center ...]
6. General University Hospital and First Faculty of Medicine Researchers Yield New Data on Myelodysplastic Syndromes (Experience with luspatercept therapy in patients with transfusion-dependent low-risk myelodysplastic syndromes in real-world ...)
7. Hematopoietic Stem Cells Undergo Differentiation State Reprogramming to Overcome Venetoclax Sensitivity in Patients with Myelodysplastic Syndromes
8. EMA validates Geron's MAA for imetelstat to treat lower risk myelodysplastic syndromes
9. Reports on Myelodysplastic Syndromes Findings from Ehime University Provide New Insights (Impact of Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation On Relapse In Patients With Myelodysplastic ...)
10. Studies Conducted at Institute of Biotechnology on Myelodysplastic Syndromes Recently Published (Inflamma-miRs Profile in Myelodysplastic Syndrome Patients)
11. European Commission Expands Approval of Bristol Myers Squibb's Reblozyl(r) (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
12. New Secondary Acute Myeloid Leukemia Findings from Sidney Kimmel Comprehensive Cancer Center Described (Ccrl2 Affects the Sensitivity of Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Cells To Azacitidine)
13. Study Data from University of California San Francisco (UCSF) Update Knowledge of Myelodysplastic Syndromes (The Management of Low-risk Myelodysplastic Syndromes-current Standards and Recent Advances)
14. Bristol Myers Squibb Granted Favorable CHMP Evaluation for Reblozyl(r) (luspatercept) in Treating Adults Affected by Transfusion-Dependent Anemia Caused by Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
15. Researchers from National Cancer Institute (NCI) Detail New Studies and Findings in the Area of Myelodysplastic Syndromes (How I Reduce and Treat Posttransplant Relapse of Mds)
16. Researcher at University of Rochester Medical Center Reports Research in Telemedicine (Adaptation of Serious Illness Care Program to be Delivered via Telehealth for Older Patients with Hematologic Malignancy) (Adaptation of Serious Illness Care ...)
17. Research from Vanderbilt University School of Medicine Reveals New Findings on Clinical Trials and Studies (The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap ...)
18. Reports Outline Myelodysplastic Syndromes Research from University of South Florida (Extramedullary Hematopoiesis in Myelodysplastic Syndromes: A Systematic Literature Review)
19. Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes
20. Notable Labs Donates $60,000 to MDS Foundation to Accelerate Progress for Patients with Myelodysplastic Syndromes
21. Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
22. Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117) in Combination with Azacitidine in Myelodysplastic Syndromes
23. Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody AK117 in Combination with Azacitidine in Myelodysplastic Syndromes
24. Heinrich-Heine-University Researchers Focus on Myelodysplastic Syndromes (Guidelines for Myelodysplastic Syndromes: Converting Evidence into Action?)
25. US FDA grants breakthrough therapy status to Roche's Venclexta in combo with azacitidine to treat myelodysplastic syndromes
26. New Research on Myelodysplastic Syndromes from First Clinical Medical College of Lanzhou University Summarized (Advances in Treatment of Transfusion-dependent Lower-risk Myelodysplastic Syndromes)
27. Investigators from H. Lee Moffitt Cancer Center and Research Institute Have Reported New Data on Myelodysplastic Syndromes [Fluorescence In Situ Hybridization (Fish) Utility for Risk Score Assessment In Patients With Mds With Normal Metaphase ...]
28. Findings from H. Lee Moffitt Cancer Center and Research Institute Reveals New Findings on Myelodysplastic Syndromes (Soho State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes)
29. New Myelodysplastic Syndromes Findings Reported from H. Lee Moffitt Cancer Center and Research Institute (Luspatercept In the Treatment of Lower-risk Myelodysplastic Syndromes)
30. Bristol Myers Squibb and Acceleron Pharma receive Health Canada approval for Reblozyl to treat myelodysplastic syndromes
31. Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes
32. First-in-Class Investigational SX-682 Demonstrated Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
33. Aprea's phase 3 trial of eprenetapopt with azacitidine versus AZA to treat TP53 mutant myelodysplastic syndromes fails to meet primary endpoint
34. Recent Reports from University Hospital Dusseldorf Highlight Findings in Myelodysplastic Syndromes (Analysis of the impact of adherence to guidelines and expert advice in patients with myelodysplastic syndromes)
35. Researchers at University of Health Sciences Release New Data on Myelodysplastic Syndromes (Lenalidomide Plus Decitabine Treatment in a Myelodysplastic Syndrome Patient With Deletion 5q and Excess Blasts)
36. US FDA grants breakthrough therapy status to Takeda's pevonedistat to treat higher-risk myelodysplastic syndromes
37. Curis begins phase 1 trial of CA-4948 in patients with AML and myelodysplastic syndromes
38. Researchers' Work from Clinical Hospital Focuses on Myelodysplastic Syndromes (Impact of Treatment Prior To Allogeneic Transplantation of Hematopoietic Stem Cells In Patients With Myelodysplastic Syndrome: Results of the Latin American Bone ...)
39. Research on Myelodysplastic Syndromes Described by Researchers at Massachusetts General Hospital (Management of patients with lower-risk myelodysplastic syndromes) (Management of patients with lower-risk myelodysplastic syndromes)
40. Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes
41. Hallym University College of Medicine Researchers Provide New Insights into Myelodysplastic Syndromes (Deep learning application of the discrimination of bone marrow aspiration cells in patients with myelodysplastic syndromes)
42. Studies from Novartis Pharmaceuticals AG Add New Findings in the Area of Artificial Intelligence (Educational and Emotional Needs of Patients With Myelodysplastic Syndromes: an Ai Analysis of Multi-country Social Media)
43. Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
44. Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes
45. Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
46. Reports from E. Balleari and Co-Researchers Add New Data to Findings in Myelodysplastic Syndromes (Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score-matched analysis)
47. Data from Massachusetts General Hospital Provide New Insights into Myelodysplastic Syndromes (Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome In Ewing and Osteosarcoma Survivors)
48. Study Results from University of Barcelona in the Area of Myelodysplastic Syndromes Reported (Epoetin alfa for the treatment of myelodysplastic syndrome-related anemia: A review of clinical data, clinical guidelines, and treatment protocols)
49. New Myelodysplastic Syndromes Study Findings Recently Were Reported by Researchers at H. Lee Moffitt Cancer Center and Research Institute [A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS)]
50. Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.